Drug Profile
Hepatocyte growth factor therapy - Kringle Pharma/ChronTech Pharma
Alternative Names: ChronSealLatest Information Update: 16 Oct 2021
Price :
$50
*
At a glance
- Originator Kringle Pharma; Tripep
- Developer ChronTech Pharma; Kringle Pharma
- Class Antifibrotics; Growth factors; Neuropsychotherapeutics
- Mechanism of Action Hepatocyte growth factor stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Leg ulcer
Most Recent Events
- 18 Jun 2014 No development reported - Phase-I/II for Leg ulcer in Norway (Topical)
- 18 Jun 2014 No development reported - Phase-I/II for Leg ulcer in Sweden (Topical)
- 21 Apr 2011 Clinical development is ongoing